January 1, 2000Journal of Vascular Research
Blockade of Angiotensin II Type 1 Receptors: Effect on Carotid and Radial Artery Structure and Function in Hypertensive Humans
Key result
Irbesartan significantly reduced radial artery wall thickness compared to placebo (-10.51% vs 6.18% change from baseline) in subjects with essential hypertension.
Why the study?
Does irbesartan reduce arterial hypertrophy and improve arterial structure/function in subjects with essential hypertension?
Population
Subjects with essential hypertension
Comparison
Irbesartan 150 mg/day for 8 weeks vs Placebo
Design
RCT, double-blind
Follow-up
8 weeks
Authors
Discussion
Loading...
Member takes
Implication
Irbesartan reduces radial artery hypertrophy independent of BP effects; extends evidence for AT1 blockade on vascular remodeling in hypertension.
Study Design
Type
RCT
Blinding
Double-blind
Structured PICO
Does irbesartan reduce arterial hypertrophy and improve arterial structure/function in subjects with essential hypertension?
P
Population
Subjects with essential hypertension treated for 8 weeks.
I
Intervention
Irbesartan 150 mg/day for 8 weeks
C
Comparator
Placebo
O
Outcome
Blood pressure, wall thickness, diameter and stiffness of the common carotid and radial arteries measured using high-resolution echotracking techniquessurrogate
Main Result
Absolute Event Rate: -10.51% vs 6.18%
An 8-week treatment with irbesartan significantly reduced radial but not carotid artery wall thickness in hypertensive patients, independent of blood pressure reduction.
Cite This Study
Bénétos et al. (2000) conducted an RCT in Essential hypertension. Irbesartan vs. Placebo was evaluated on Percent change from baseline in radial artery wall thickness. Irbesartan significantly reduced radial artery wall thickness compared to placebo (-10.51% vs 6.18% change from baseline) in subjects with essential hypertension.